Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RHU.0000000000001200 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of omalizumab therapy in urticaria vasculitis.
Front Allergy
July 2022
Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclonal antibody, has been successfully used to treat few cases of severe and/or refractory UV. In this study we report our experience on 6 patients with refractory normocomplementemic UV successfully treated with anti-IgE therapy (OMA), suggesting that this biological therapy may be a safe and effective therapeutic option in UV.
View Article and Find Full Text PDFSuccessful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.
Asian Pac J Allergy Immunol
December 2020
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Urticarial vasculitis (UV) is a rare form of cutaneous leukocytoclastic vasculitis with persistent urticarial lesions. UV may be severe and refractory to standard treatment including antihistamines, anti-inflammatories, antimalarials, corticosteroids and immunosuppressants. Omalizumab, an anti-IgE antibody, is approved for chronic spontaneous urticaria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!